Syndax Pharmaceuticals has received FDA approval for a new drug, Revuforj, to treat advanced cases of acute leukemia with a specific genetic signature. It is the first therapy in a new class of medicines for blood cancers and is approved for adults and children over the age of 1. Revuforj works by inhibiting a protein called menin in patients with a KMT2A gene rearrangement. Clinical trials showed promising results, with some patients achieving complete remission. The drug comes with warnings of potential side effects, but it represents a significant advancement in the treatment of leukemia.
Source link
Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval
